Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

Jason Chesney, Igor Puzanov, Frances Collichio, Mohammed M. Milhem, Axel Hauschild, Lisa Chen, Anjali Sharma, Claus Garbe, Parminder Singh, Janice M. Mehnert

Research output: Contribution to journalArticle

Abstract

Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB–IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response). Patients without pseudo-progression were classified by whether they responded within or after 6 months of treatment start; those with pseudo-progression were classified by whether pseudo-progression was due to increase in existing lesions or development of new lesions. Overall, 39% (n = 38/98) in the combination arm and 18% (n = 18/100) in the ipilimumab arm had an objective response. Eight responders (combination, n = 7 [18.4%]; ipilimumab, n = 1 [5.6%]) had pseudo-progression; most occurred by week 12 and were caused by an increase in existing lesions. These data reinforce use of T-VEC through initial progression when combined with checkpoint inhibitors. Trial Registration NCT01740297 (ClinicalTrials.gov; date of registration, December 4, 2012); 2012-000307-32 (ClinicalTrialsRegister.eu; date of registration, May 13, 2014).

Original languageEnglish (US)
Pages (from-to)417-420
Number of pages4
JournalBritish journal of cancer
Volume121
Issue number5
DOIs
StatePublished - Aug 27 2019

Fingerprint

Melanoma
Tumor Burden
ipilimumab
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. / Chesney, Jason; Puzanov, Igor; Collichio, Frances; Milhem, Mohammed M.; Hauschild, Axel; Chen, Lisa; Sharma, Anjali; Garbe, Claus; Singh, Parminder; Mehnert, Janice M.

In: British journal of cancer, Vol. 121, No. 5, 27.08.2019, p. 417-420.

Research output: Contribution to journalArticle

Chesney, J, Puzanov, I, Collichio, F, Milhem, MM, Hauschild, A, Chen, L, Sharma, A, Garbe, C, Singh, P & Mehnert, JM 2019, 'Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma', British journal of cancer, vol. 121, no. 5, pp. 417-420. https://doi.org/10.1038/s41416-019-0530-6
Chesney, Jason ; Puzanov, Igor ; Collichio, Frances ; Milhem, Mohammed M. ; Hauschild, Axel ; Chen, Lisa ; Sharma, Anjali ; Garbe, Claus ; Singh, Parminder ; Mehnert, Janice M. / Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. In: British journal of cancer. 2019 ; Vol. 121, No. 5. pp. 417-420.
@article{b86ec348da6a4488892c618d4c485751,
title = "Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma",
abstract = "Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB–IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25{\%} increase in tumour burden before response). Patients without pseudo-progression were classified by whether they responded within or after 6 months of treatment start; those with pseudo-progression were classified by whether pseudo-progression was due to increase in existing lesions or development of new lesions. Overall, 39{\%} (n = 38/98) in the combination arm and 18{\%} (n = 18/100) in the ipilimumab arm had an objective response. Eight responders (combination, n = 7 [18.4{\%}]; ipilimumab, n = 1 [5.6{\%}]) had pseudo-progression; most occurred by week 12 and were caused by an increase in existing lesions. These data reinforce use of T-VEC through initial progression when combined with checkpoint inhibitors. Trial Registration NCT01740297 (ClinicalTrials.gov; date of registration, December 4, 2012); 2012-000307-32 (ClinicalTrialsRegister.eu; date of registration, May 13, 2014).",
author = "Jason Chesney and Igor Puzanov and Frances Collichio and Milhem, {Mohammed M.} and Axel Hauschild and Lisa Chen and Anjali Sharma and Claus Garbe and Parminder Singh and Mehnert, {Janice M.}",
year = "2019",
month = "8",
day = "27",
doi = "10.1038/s41416-019-0530-6",
language = "English (US)",
volume = "121",
pages = "417--420",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

AU - Chesney, Jason

AU - Puzanov, Igor

AU - Collichio, Frances

AU - Milhem, Mohammed M.

AU - Hauschild, Axel

AU - Chen, Lisa

AU - Sharma, Anjali

AU - Garbe, Claus

AU - Singh, Parminder

AU - Mehnert, Janice M.

PY - 2019/8/27

Y1 - 2019/8/27

N2 - Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB–IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response). Patients without pseudo-progression were classified by whether they responded within or after 6 months of treatment start; those with pseudo-progression were classified by whether pseudo-progression was due to increase in existing lesions or development of new lesions. Overall, 39% (n = 38/98) in the combination arm and 18% (n = 18/100) in the ipilimumab arm had an objective response. Eight responders (combination, n = 7 [18.4%]; ipilimumab, n = 1 [5.6%]) had pseudo-progression; most occurred by week 12 and were caused by an increase in existing lesions. These data reinforce use of T-VEC through initial progression when combined with checkpoint inhibitors. Trial Registration NCT01740297 (ClinicalTrials.gov; date of registration, December 4, 2012); 2012-000307-32 (ClinicalTrialsRegister.eu; date of registration, May 13, 2014).

AB - Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB–IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response). Patients without pseudo-progression were classified by whether they responded within or after 6 months of treatment start; those with pseudo-progression were classified by whether pseudo-progression was due to increase in existing lesions or development of new lesions. Overall, 39% (n = 38/98) in the combination arm and 18% (n = 18/100) in the ipilimumab arm had an objective response. Eight responders (combination, n = 7 [18.4%]; ipilimumab, n = 1 [5.6%]) had pseudo-progression; most occurred by week 12 and were caused by an increase in existing lesions. These data reinforce use of T-VEC through initial progression when combined with checkpoint inhibitors. Trial Registration NCT01740297 (ClinicalTrials.gov; date of registration, December 4, 2012); 2012-000307-32 (ClinicalTrialsRegister.eu; date of registration, May 13, 2014).

UR - http://www.scopus.com/inward/record.url?scp=85069879114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069879114&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0530-6

DO - 10.1038/s41416-019-0530-6

M3 - Article

VL - 121

SP - 417

EP - 420

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -